~~<i id='CBAB842D49'><strike id='CBAB842D49'><tt id='CBAB842D49'><pre id='CBAB842D49'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：comprehensive 2025-10-02 20:01:17 Page View：367

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anthos stroke drug appears safer than common blood thinner
Next article： Activists slam private health insurers over coverage restrictions

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Why psychiatrists like me stop taking insurance

Adobe“I’msorry,butI’munabletotakeonnewpatientsatthistime.”I’vesaidthatlinehundredsoftimesinthe15year

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

How a scoliosis diagnosis changed the life of one young dancer

Photoillustration:CaseySheneryforSTATMaddyWelzalwayslovedtodance.Evenbeforeshelearnedhowtotieherowns